Rogers Corporation (ROG) Posts Q3 EPS of $0.44, Tops EPS Estimates; Guides
More News related to ROG
- Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
- 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
- New Cancer Research Tool: Roche's CIM-Plate 16 Enables Real-Time Analysis of Cell Migration on the xCELLigence System
- Eurofins MWG Operon Joins Roche NimbleGen's Certified Service Provider Program for Targeted Enrichment and Sequencing Services
- FDA Grants Emergency Use Authorization to Roche s Assay for 2009 H1N1 Influenza Virus
More News related to Earnings
- Quicksilver Resources (KWK) Granted Motion for Partial Summary by Texas in BreitBurn (BBEP) Lawsuit
- American International Group (AIG) Implementing Benmosche's Compensation Agreement
- Sun American (SAMB) Receives Listing Rule 5450 Notification from NASDAQ
- Solutia (SOA) To Discontinue Manufacturing at its Plant in Cologne, Germany
- General Dynamics (GD) Business Unit Awarded $2.2B U.S. Army SAC Contract for 724 LAV's
Rogers Corporation (NYSE: ROG) reports Q3 EPS of $0.44, 12 cents better than the analyst estimate of $0.32. Revenue for the quarter was $81 million, which compares to the estimate of $76 million.
Sees Q409 EPS of $0.30 - $0.36, versus $0.23 consensus.
Sees Q4 Sales $73 - $77 million, versus $72 million consensus.
Related Categories
EarningsStocks Mentioned
-0.61Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
